Fredag 6 December | 21:44:22 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-02-06 08:30 Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-10-30 - Split EXPRS2 40:1
2024-08-15 - Kvartalsrapport 2024-Q2
2024-06-07 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2024-06-05 - Årsstämma
2024-05-16 - Kvartalsrapport 2024-Q1
2024-02-08 - Bokslutskommuniké 2023
2023-11-16 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-25 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2023-05-24 - Årsstämma
2023-05-16 - Kvartalsrapport 2023-Q1
2023-03-23 - Extra Bolagsstämma 2023
2023-02-09 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-31 - Kvartalsrapport 2022-Q1
2022-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2022-05-25 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2021-05-26 - Årsstämma
2021-05-19 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-09-23 - Extra Bolagsstämma 2020
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2020-05-26 - Årsstämma
2020-05-20 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-24 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2019-05-23 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-28 - Bokslutskommuniké 2018
2018-11-22 - Kvartalsrapport 2018-Q3
2018-08-24 - Kvartalsrapport 2018-Q2
2018-05-25 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2018-05-24 - Årsstämma
2018-05-17 - Kvartalsrapport 2018-Q1
2018-02-07 - Bokslutskommuniké 2017
2017-11-30 - Kvartalsrapport 2017-Q3
2017-08-31 - Kvartalsrapport 2017-Q2
2017-06-01 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2017-05-31 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1
2017-04-19 - Extra Bolagsstämma 2017
2017-02-28 - Bokslutskommuniké 2016
2016-11-08 - Kvartalsrapport 2016-Q3
2016-08-31 - Kvartalsrapport 2016-Q2

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
ExpreS2ion Biotech Holding är ett forsknings- och utvecklingsbaserat bolag med en patenterad plattform inom bioteknisk proteinproduktion. Bolaget har sin egen utvecklingspipeline av vaccinkandidater inom COVID-19, bröstcancer, influensa och malaria. Dessutom har bolaget intäkter från försäljning av tillverkningstjänster och plattformslicenser. Bolaget startade 2010 och har sin verksamhet i DTU Forskerpark i Hørsholm.
2024-06-26 09:00:00

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. FOR MORE INFORMATION, SEE THE SECTION IMPORTANT INFORMATION BELOW.

Hørsholm, Denmark, 26 June 2024 - Tomorrow, 27 June 2024, is the last day of the subscription period in ExpreS2ion Biotech Holding AB's ("ExpreS2ion" or the "Company") rights issue of shares and warrants of series TO 10 and TO 11 ("Units") (the "Rights Issue"), which was resolved by the Board of Directors on 2 May 2024, and approved by the Annual General Meeting held on 5 June 2024.

Subscription is possible via subscription form and some banks and brokers' websites

It is possible to subscribe via the subscription form found on ExpreS[2]ion's investor website (https://investor.expres2ionbio.com/rights-issue-2024/), as well as digitally via Vator Securities' website (https://vatorsecurities.se/sv/emissioner/expres2ion-biotech-holding/) under `Offers.'

Some banks and brokers no longer offer subscription via their websites. The subscription form will be available the entire subscription period.

Publication of the prospectus

For complete information about the Rights Issue, please refer to the prospectus that has been prepared by the Company and approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) (the "SFSA"). The prospectus is available in Swedish and English on ExpreS2ion's website (https://investor.expres2ionbio.com/) and is also available on the SFSA's website (https://fi.se/sv/vara-register/prospektregistret/).

The Rights Issue in brief
  • The subscription price has been set to SEK 1.00 per Unit, corresponding to SEK 1.00 per share. The warrants of series TO 10 and warrants of series TO 11 are issued free of charge. Upon full subscription in the Rights Issue, the Company will receive initial proceeds of approximately SEK 60 million before deduction of transaction costs.

  • Upon full subscription in the Rights Issue, the net proceeds from the Rights Issue will be used for (i) ES2B-C001 clinical phase initiation and progression, (ii) early preclinical development of a cytomegalovirus vaccine candidate, (iii) internal costs related to grant-sponsored projects and (iv) working capital including discovery pipeline and platform development.

  • Existing shareholders in ExpreS2ion as of the record date, 10 June 2024, received seven (7) unit rights for each existing share. Six (6) unit rights entitle to subscription of one (1) Unit in the rights issue.

  • In total, a maximum of 59,972,451 Units can be issued. Each Unit consists of one (1) share, one (1) warrant of series TO 10 and one (1) warrant of series TO 11, which means that a maximum of 59,972,451 shares, 59,972,451 warrants of series TO 10 and 59,972,451 warrants of series TO 11 can be issued.

  • The subscription period runs from and including 12 June 2024 until and including 27 June 2024.

  • Warrants of series TO 10 can be exercised for subscription of shares in the Company during the period from and including 20 November 2024 until and including 4 December 2024. Warrants of series TO 11 can be exercised for subscription of shares in the Company during the period from and including 18 September 2025 until and including 2 October 2025.

Timetable for the Rights Issue

Subscription period 12 June 2024 - 27 June 2024
Trading in BTUs (paid 12 June 2024 until the Rights Issue is
subscribed Units) registered with the Swedish Companies
Registration Office
Announcement of On or around 1 July 2024
outcome in the Rights
Issue

Advisors

Vator Securities acts as financial advisor and issuing agent to the Company in connection with the Rights Issue. Schjødt is the Company's legal advisor in connection with the Rights Issue.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB

The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company's news distributor, Cision, at the publication of this press release.

IMPORTANT INFORMATION

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in ExpreS2ion in any jurisdiction, neither from ExpreS2ion nor from someone else.

This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness. Vator Securities is acting for ExpreS2ion in connection with the Rights Issue and no one else and will not be responsible to anyone other than ExpreS2ion for providing the protections afforded to its clients nor for giving advice in relation to the Rights Issue or any other matter referred to herein.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public Rights Issue of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the Unites States, Australia, Canada, Hong Kong, Japan, New Zeeland, Singapore, South Africa or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. Any acquisition of Units in ExpreS2ion in the Rights Issue should only be made on the basis of the information contained in the formal prospectus issued in connection with the Rights Issue, which was approved by the Swedish Financial Supervisory Authority on 5 June 2024 and is held available on the Company's website, www.expres2ionbio.com. In accordance with article 2 k of the Prospectus Regulation this press release constitutes an advertisement.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is not required by law or Nasdaq First North Growth Market rule book for issuers.

Information to distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in ExpreS2ion have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the shares in ExpreS2ion may decline and investors could lose all or part of their investment; the shares in ExpreS2ion offer no guaranteed income and no capital protection; and an investment in the shares in ExpreS2ion is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Rights Issue.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in ExpreS2ion.

Each distributor is responsible for undertaking its own target market assessment in respect of the shares in ExpreS2ion and determining appropriate distribution channels.